The lower the bad cholesterol gets with evolocumab, the lower the risk of heart problems—even when cholesterol drops to very low levels, there’s still added protection, and no ‘too low’ point has been found.
Evidence from Studies
Supporting (1)
Community contributions welcome
The study looked at a drug called evolocumab that lowers bad cholesterol, and found that the lower the cholesterol goes, the more heart protection patients get — even at very low levels.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Confirm the consistency of the LDL-C–CVD risk relationship across multiple agents and populations.
A meta-regression of individual patient data from all major lipid-lowering RCTs (statins, ezetimibe, PCSK9i, bempedoic acid), analyzing the slope of the relationship between on-treatment LDL-C and MACE risk, with assessment of linearity and threshold effects.
Establish causality in the dose-response relationship by randomizing to different LDL-C targets.
A factorial RCT randomizing 20,000 ASCVD patients to evolocumab vs placebo and within each arm to treat-to-target LDL-C <0.5 mmol/L vs <1.8 mmol/L, comparing MACE rates over 5 years.
Validate the association in diverse real-world populations.
A prospective cohort of 100,000 ASCVD patients on PCSK9 inhibitors, tracking achieved LDL-C and MACE over 5 years, using time-varying Cox models to assess the LDL-C–outcome relationship.